Susan Tantawi – Page 2 – Galecto, Inc.

About Susan Tantawi

This author has not written his bio yet.
But we are proud to say that Susan Tantawi contributed 14 entries already.

Entries by Susan Tantawi

Galecto raises €79M to run late-phase IPF trial

January 11, 2019

Galecto Biotech has raised €79 million ($90 million) to take its treatment for idiopathic pulmonary fibrosis (IPF) into a phase 2/3 trial.

CFO-karrusel: To danske biotekfirmaer får nye finanschefer

January 11, 2019

To danske biotekselskaber får nye mænd til at styre finanserne. Den ene er samtidigt finansdirektør for et tredje dansk selskab med rødder i Novozymes.

Video: BIO-Europe® 2018_ Galecto Biotech’s CMO discusses the company’s recent EUR 79m Series C financing

January 10, 2019

Richard Marshall, chief medical officer at Galecto Biotech, talks to Scrip managing editor Joe Shorthouse about how a recent financing will allow the galectin modulator company to quickly push forward its product for idiopathic pulmonary fibrosis. He also discusses the company’s work in the oral and ocular therapeutic areas.

Galecto Biotech Raises €79 Million in Series C Financing Co-Led by Ysios Capital and OrbiMed to Advance Galectin Inhibitor to Late-Stage Clinical Development

October 26, 2018

Galecto Biotech AB, the leading developer of galectin modulators for the treatment of severe diseases, including fibrosis and cancer, today announced the successful closing of a €79 million series C financing co-led by Ysios Capital and OrbiMed. New investors Ysios Capital, OrbiMed, HBM Healthcare Investments, OrbiMed Israel, Bristol Myers-Squibb, Maverick Ventures and Seventure Partners joined existing investors Novo Seeds, M Ventures, and Sunstone Capital in the financing round. Concurrent with the financing, Karen Wagner (Ysios Capital), Chau Khuong (OrbiMed), Chandra Leo (HBM) and Erez Chimovits (OrbiMed Israel) were appointed to the Galecto Board of Directors.

About Susan Tantawi

Entries by Susan Tantawi

Follow us